Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer

Published on 05/31/2025 at 08:08

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about NovoCure Limited

Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	Jul. 08	MT
Novocure to Present Final Secondary Endpoint Data from the Phase 3 Panova-3 Trial of Tumor Treating Fields in Pancreatic Cancer At the Esmo Gastrointestinal Cancers Congress 2025	Jul. 01	CI
Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing	Jun. 04	MT
NovoCure Limited - Special Call	Jun. 02
Zai Lab and Novocure Announce Results from the Phase 3 Panova-3 Trial of Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 Asco Annual Meeting	May. 31	CI
Novocure Says Ttfields Therapy Shows Significant Improvement In Overall Survival For Pancreatic Cancer	May. 31	RE
Novocure Announces Results from the Phase 3 Panova-3 Trial of Novocure's Tumor Treating Fields Therapy for Pancreatic Cancer to Be Presented At 2025 ASCO Annual Meeting	May. 31	CI
Novocure Announces Upcoming Investor Events	May. 27	RE
NovoCure's Q1 Loss Narrows, Revenue Rises	Apr. 24	MT
NovoCure Limited, Q1 2025 Earnings Call, Apr 24, 2025	Apr. 24
Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $155M, vs. FactSet Est of $146.9M	Apr. 24	MT
Earnings Flash (NVCR) NOVOCURE Posts Q1 Loss $-0.31 Per Share, vs. FactSet Est of $-0.46	Apr. 24	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of Its Tumor Treating Fields Therapy for Pancreatic Cancer as A Late-Breaking Oral Presentation At the 2025 ASCO Annual Meeting	Apr. 23	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Apr. 22	MT
NovoCure Says Optune Lua Device Gets CE Mark to Treat Lung Cancer	Apr. 22	MT
Novocure'S Optune Lua® Receives CE Mark Approval	Apr. 22	RE
Novocure Insider Sold Shares Worth $266,126, According to a Recent SEC Filing	Mar. 03	MT
Novocure Insider Sold Shares Worth $296,257, According to a Recent SEC Filing	Mar. 03	MT
NovoCure's Q4 Loss Widens, Revenue Rises	Feb. 27	MT
NovoCure Limited, Q4 2024 Earnings Call, Feb 27, 2025	Feb. 27
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $161.3M, vs. FactSet Est of $161.3M	Feb. 27	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Feb. 27	CI
NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 27	CI
C Worldwide Healthcare Select up 5.8% in January - divests Illumina	Feb. 12	FW

NOVOCURE LIMITED

Stock

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-18 pm EDT
16.02 ^USD	-1.17%

More quotes

Chart

Duration

Period

NVCR: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Weekly market update: Earnings Wave Ahead

Ashish Kacholia and Dolly Khanna: India's Star Investors Send Portfolio Signals

July 18, 2025 at 05:13 am EDT

Employment figures offer some respite for the Bank of England

July 17, 2025 at 10:25 am EDT

Results preview: Legrand accelerates

July 17, 2025 at 05:51 am EDT

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 05:24 am EDT

When volatility boosts US banks

July 17, 2025 at 04:42 am EDT

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 03:20 am EDT

Perplexity in talks with phone makers to pre-install Comet AI mobile browser on devices

July 18, 2025 at 06:44 pm EDT

Union Pacific, Norfolk Southern explore cross-continental railroad merger, source says

July 18, 2025 at 05:46 pm EDT

AI models with systemic risks given pointers on how to comply with EU AI rules

July 18, 2025 at 05:19 pm EDT

All our articles